SCHEMBL7714603

SCHEMBL7714603

CN1CCN(c2nc(N)ncc2Cc2ccccc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 13/20 0.57
▸ HTR6 P50406 2/20 0.54
▸ HRH1 P35367 1/20 0.53
▸ KCNH2 Q12809 1/20 0.45
▸ HRH3 Q9Y5N1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7714282 0.88 HRH4 (0.56) HRH4HTR6KCNH2HRH3
SCHEMBL7714720 0.88 HRH4 (0.52) HRH4HTR6KCNH2HRH3
SCHEMBL7708456 0.87 HRH4 (0.55) HRH4HTR6KCNH2HRH3
SCHEMBL7708547 0.87 HTR6 (0.56) HRH4HTR6KCNH2HRH3
SCHEMBL7712449 0.87 HTR6 (0.56) HRH4HTR6KCNH2HRH3
SCHEMBL7708441 0.85 TSHR (0.57) HRH4HTR6HRH1
SCHEMBL7716594 0.85 HTR6 (0.58) HRH4HTR6
SCHEMBL7713555 0.85 HRH4 (0.52) HRH4HTR6KCNH2HRH3
SCHEMBL7708586 0.85 KDM4E (0.46) HRH4HRH1
SCHEMBL7708466 0.84 SMN1; SMN2 (0.55) HRH4HTR6HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1025091-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE OR NEUROLOGICAL DISORDERS OF THE CENTRAL NERVOUS SYSTEM Krenitsky Pharmaceuticals, Inc. (US) 2000-08-09 — — EP claimed
WO-1999019305-A2 SUBSTITUTED PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE OR NEUROLOGICAL DISORDERS OF THE CENTRAL NERVOUS SYSTEM KRENITSKY PHARMACEUTICALS INC. (US) 1999-04-22 — — WO claimed
US-6440965-B1 Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system KRENITSKY PHARMACEUTICALS, INC. 2002-08-27 — — US disclosed
Send feedback